Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients - PubMed (original) (raw)
Clinical Trial
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
H Fukaura et al. J Clin Invest. 1996.
Abstract
Oral administration of antigen is a long recognized method of inducing systemic immune tolerance. In animals with experimental autoimmune disease, a major mechanism of oral tolerance triggered by oral administration of antigen involves the induction of regulatory T cells that mediate active suppression by secreting the cytokine TGF-beta 1. Multiple sclerosis (MS) is a presumed T cell-mediated Th1 type autoimmune disease. Here, we investigated whether in MS patients oral myelin treatment, containing both myelin basic protein (MBP) and proteolipid protein (PLP), induced antigen specific MBP or PLP reactive T cells that either secreted IL4, TGF-beta1, or alternatively did Th1 type sensitization occur as measured by IFN-gamma secretion. Specifically, 4,860 short-term T cell lines were generated to either MBP, PLP, or tetanus toxoid (TT) from 34 relapsing-remitting MS patients: 17 orally treated with bovine myelin daily for a minimum of 2 yr as compared to 17 nontreated patients. We found a marked increase in the relative frequencies of both MBP and PLP specific TGF-beta1-secreting T cell lines in the myelin treated MS patients as compared to non-treated MS patients (MBP P < 0.001, PLP P < 0.003). In contrast, no change in the frequency of MBP or PLP specific IFN-gamma or TT specific TGF-beta1 secreting T cells were observed. These results suggest that the oral administration of antigens generates antigen specific TGF-beta1 secreting Th3 cells of presumed mucosal origin that represent a distinct lineage of T cells. Since antigen-specific TGF-beta1 secreting cells localize to the target organ and then suppress inflammation in the local microenvironment, oral tolerization with self antigens may provide a therapeutic approach for the treatment of cell-mediated autoimmune disease which does not depend upon knowledge of the antigen specificity of the original T cell clone triggering the autoimmune cascade.
Similar articles
- Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis.
Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H. Hafler DA, et al. Ann N Y Acad Sci. 1997 Dec 19;835:120-31. doi: 10.1111/j.1749-6632.1997.tb48623.x. Ann N Y Acad Sci. 1997. PMID: 9616767 Clinical Trial. - Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis.
Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Fukaura H, et al. Ann N Y Acad Sci. 1996 Feb 13;778:251-7. doi: 10.1111/j.1749-6632.1996.tb21133.x. Ann N Y Acad Sci. 1996. PMID: 8610978 - T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls.
Hellings N, Barée M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. Hellings N, et al. J Neurosci Res. 2001 Feb 1;63(3):290-302. doi: 10.1002/1097-4547(20010201)63:3<290::AID-JNR1023>3.0.CO;2-4. J Neurosci Res. 2001. PMID: 11170179 - Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.
Weiner HL. Weiner HL. Microbes Infect. 2001 Sep;3(11):947-54. doi: 10.1016/s1286-4579(01)01456-3. Microbes Infect. 2001. PMID: 11564443 Review. - Immune tolerance to myelin proteins.
Seamons A, Perchellet A, Goverman J. Seamons A, et al. Immunol Res. 2003;28(3):201-21. doi: 10.1385/IR:28:3:201. Immunol Res. 2003. PMID: 14713715 Review.
Cited by
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.
Song Y, Li J, Wu Y. Song Y, et al. Signal Transduct Target Ther. 2024 Oct 4;9(1):263. doi: 10.1038/s41392-024-01952-8. Signal Transduct Target Ther. 2024. PMID: 39362875 Free PMC article. Review. - Bibliometric analysis of global research trends on regulatory T cells in neurological diseases.
Gao Q, Li X, Li Y, Long J, Pan M, Wang J, Yang F, Zhang Y. Gao Q, et al. Front Neurol. 2023 Oct 12;14:1284501. doi: 10.3389/fneur.2023.1284501. eCollection 2023. Front Neurol. 2023. PMID: 37900596 Free PMC article. - Recombinant MBP-pσ1 expressed in soybean seeds delays onset and reduces developing disease in an animal model of multiple sclerosis.
Robles LM, Reichenberg LH, Grissom Ⅲ JH, Chi RJ, Piller KJ. Robles LM, et al. Plant Biotechnol (Tokyo). 2022 Dec 25;39(4):367-379. doi: 10.5511/plantbiotechnology.22.0926a. Epub 2022 Dec 16. Plant Biotechnol (Tokyo). 2022. PMID: 37283612 Free PMC article. - Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential.
Huldani H, Rashid AI, Turaev KN, Opulencia MJC, Abdelbasset WK, Bokov DO, Mustafa YF, Al-Gazally ME, Hammid AT, Kadhim MM, Ahmadi SH. Huldani H, et al. Cell Commun Signal. 2022 Oct 26;20(1):167. doi: 10.1186/s12964-022-00972-7. Cell Commun Signal. 2022. PMID: 36289525 Free PMC article. Review. - Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity.
Richardson N, Wraith DC. Richardson N, et al. Immunother Adv. 2021 May 22;1(1):ltab009. doi: 10.1093/immadv/ltab009. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919740 Free PMC article. Review.
References
- J Biol Chem. 1976 May 10;251(9):2671-9 - PubMed
- Immunol Today. 1996 Mar;17(3):138-46 - PubMed
- Nature. 1985 Sep 26-Oct 2;317(6035):355-8 - PubMed
- Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6 - PubMed
- Clin Exp Immunol. 1986 Jun;64(3):581-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous